Takashi Kawahara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takashi Kawahara has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Hiroyuki Nishiyama
Department of Urology, Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
18 shared publications - Masatoshi Eto
Department of Urology, Graduate School of Medical Sciences Kyushu University Fukuoka Japan
13 shared publications - Akito Terai
10Department of Urology, Kurashiki Central Hospital, Kurashiki, Japan
12 shared publications - Haruhito Azuma
Department of Urology, Faculty of Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan
12 shared publications - Hideaki Miyake
Division of Urology Kobe University Graduate School of Medicine Hyogo Japan
12 shared publications - Hiroji Uemura
Departments of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan
12 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (8)
Efficacy of Nivolumab in Chemotherapy‐Resistant Mesothelioma of the Tunica Vaginalis Testis: A Case Report
Background: Mesothelioma of the tunica vaginalis testis is a rare neoplasm, accounting for less than 1% of all mesothelioma cases. Due to the rarity of this disease, a standard treatment has not been established. Clinical management is generally adapted from the strategies used for pleural mesothelioma. Although immune checkpoint inhibitors (ICIs) have demonstrated efficacy in treating pleural mesothelioma, their role in mesothelioma of the tunica vaginalis testis remains uncharacterized due to a lack of evidence. This is the first report documenting a clinical response to nivolumab in chemoresistant mesothelioma of the tunica vaginalis testis. Case: A 71‐year‐old man presented with painless left scrotal swelling and was initially diagnosed with a hydrocele at the referring hospital. One year later, hydrocelectomy revealed partial thickening of the tunica without malignancy. A subsequent magnetic resonance imaging analysis revealed a new intratesticular nodule. Orchiectomy was performed, and the pathological findings revealed an epithelioid mesothelioma. He was referred to Tsukuba University Hospital for further treatment. He also had a history of Self‐Defense Force service, which suggested possible asbestos exposure. Imaging revealed pelvic lymphadenopathy with fluorodeoxyglucose uptake in the right external iliac lymph nodes. He received four cycles of cisplatin and pemetrexed every 3 weeks, resulting in stable disease. Bilateral pelvic lymph node dissection was performed and confirmed the presence of metastatic mesothelioma. Nine months after the surgery, bilateral inguinal lymph node recurrence occurred, and he received cisplatin monotherapy because of renal impairment. Despite four additional cycles of cisplatin monotherapy, the disease progressed. Therefore, chemotherapy was discontinued, and nivolumab was administered. Nivolumab resulted in sustained tumor shrinkage. However, after 3 months of treatment, he developed immune‐related encephalitis requiring corticosteroid therapy and nivolumab discontinuation. After 16 months of nivolumab initiation, he was dead from the disease. Conclusion: This is the first report documenting the clinical response of a chemoresistant mesothelioma of the tunica vaginalis testis to nivolumab. ICIs are a promising treatment option for this rare and challenging disease.
- 14 August 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (8)
Open AccessEfficacy of Nivolumab in Chemotherapy‐Resistant Mesothelioma of the Tunica Vaginalis Testis: A Case Report
Background: Mesothelioma of the tunica vaginalis testis is a rare neoplasm, accounting for less than 1% of all mesothelioma cases. Due to the rarity of this disease, a standard treatment has not been established. Clinical management is generally adapted from the strategies used for pleural mesothelioma. Although immune checkpoint inhibitors (ICIs) have demonstrated efficacy in treating pleural mesothelioma, their role in mesothelioma of the tunica vaginalis testis remains uncharacterized due to a lack of evidence. This is the first report documenting a clinical response to nivolumab in chemoresistant mesothelioma of the tunica vaginalis testis. Case: A 71‐year‐old man presented with painless left scrotal swelling and was initially diagnosed with a hydrocele at the referring hospital. One year later, hydrocelectomy revealed partial thickening of the tunica without malignancy. A subsequent magnetic resonance imaging analysis revealed a new intratesticular nodule. Orchiectomy was performed, and the pathological findings revealed an epithelioid mesothelioma. He was referred to Tsukuba University Hospital for further treatment. He also had a history of Self‐Defense Force service, which suggested possible asbestos exposure. Imaging revealed pelvic lymphadenopathy with fluorodeoxyglucose uptake in the right external iliac lymph nodes. He received four cycles of cisplatin and pemetrexed every 3 weeks, resulting in stable disease. Bilateral pelvic lymph node dissection was performed and confirmed the presence of metastatic mesothelioma. Nine months after the surgery, bilateral inguinal lymph node recurrence occurred, and he received cisplatin monotherapy because of renal impairment. Despite four additional cycles of cisplatin monotherapy, the disease progressed. Therefore, chemotherapy was discontinued, and nivolumab was administered. Nivolumab resulted in sustained tumor shrinkage. However, after 3 months of treatment, he developed immune‐related encephalitis requiring corticosteroid therapy and nivolumab discontinuation. After 16 months of nivolumab initiation, he was dead from the disease. Conclusion: This is the first report documenting the clinical response of a chemoresistant mesothelioma of the tunica vaginalis testis to nivolumab. ICIs are a promising treatment option for this rare and challenging disease.
- Open Access
Prognosis of Penile Squamous Cell Carcinoma and Extramammary Paget Disease in Japan: An Analysis of Nationwide Hospital-Based Cancer Registry Data
Background/Objectives: Penile malignant tumors are rare neoplasms, and both clinicopathologic features and prognoses remain unclear in Japanese patients. Here, we investigated the prognoses of penile malignant tumors in Japan using the nationwide hospital-based cancer registry (HBCR) database. Methods: The 2015 HBCR database cohort was queried to identify patients with penile malignant tumors. Moreover, we investigated age, pathology, tumor–node–metastases classification, first-course treatment, and overall survival in these patients. Results: A total of 269 patients were analyzed from the 2015 cohort (149 squamous cell carcinoma [SCC] patients and 56 extramammary Paget disease [EMPD] patients). The median ages at diagnosis in both SCC and EMPD patients were 76.0 and 76.5 years. The median observation period was 53 months in the present study. The 5-year overall survival (OS) rates of SCC and EMPD were 56.8% and 78.5%. The 5-year OS rates of clinical stages 0–I, II, III, and IV were (respectively) 68.0%, 70.1%, 38.5%, and 11.9% in SCC patients and (respectively) 83.7%, 83.3%, not evaluated, and 0% in patients with EMPD. Conclusions: We revealed the OS of Japanese patients with penile SCC and EMPD in a large population-based study for the first time. Patients with clinical stage IV penile SCC and EMPD had extremely poor prognoses, highlighting a need for improved disease management in these patients.
Open AccessPrognosis of Penile Squamous Cell Carcinoma and Extramammary Paget Disease in Japan: An Analysis of Nationwide Hospital-Based Cancer Registry Data
Background/Objectives: Penile malignant tumors are rare neoplasms, and both clinicopathologic features and prognoses remain unclear in Japanese patients. Here, we investigated the prognoses of penile malignant tumors in Japan using the nationwide hospital-based cancer registry (HBCR) database. Methods: The 2015 HBCR database cohort was queried to identify patients with penile malignant tumors. Moreover, we investigated age, pathology, tumor–node–metastases classification, first-course treatment, and overall survival in these patients. Results: A total of 269 patients were analyzed from the 2015 cohort (149 squamous cell carcinoma [SCC] patients and 56 extramammary Paget disease [EMPD] patients). The median ages at diagnosis in both SCC and EMPD patients were 76.0 and 76.5 years. The median observation period was 53 months in the present study. The 5-year overall survival (OS) rates of SCC and EMPD were 56.8% and 78.5%. The 5-year OS rates of clinical stages 0–I, II, III, and IV were (respectively) 68.0%, 70.1%, 38.5%, and 11.9% in SCC patients and (respectively) 83.7%, 83.3%, not evaluated, and 0% in patients with EMPD. Conclusions: We revealed the OS of Japanese patients with penile SCC and EMPD in a large population-based study for the first time. Patients with clinical stage IV penile SCC and EMPD had extremely poor prognoses, highlighting a need for improved disease management in these patients.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S5 from TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor—Naïve Locally Advanced or Metastatic Urothelial Carcinoma
Table S1, Table S2, Table S3, Table S4, Table S5
- Open Access
Pathological Predictors of Limited Salvage Radiotherapy Efficacy After Radical Prostatectomy: Central Review of JCOG0401
Background/Objectives: The multicenter randomized trial JCOG0401 showed that initial salvage radiotherapy (SRT) before salvage hormonal therapy (SHT) significantly prolonged time to treatment failure (TTF) compared with SHT alone. This central pathology analysis aimed to explore pathological features potentially associated with reduced relative benefit from SRT, while distinguishing prognostic from predictive effects. Methods: We re-analyzed 167 patients from JCOG0401 (SHT: 81, SRT ± SHT: 86). Prostatectomy specimens were re-evaluated, focusing on tertiary Gleason pattern (GP) 5 and intraductal carcinoma of the prostate (IDC-P). Cox proportional hazards models assessed exploratory interaction effects between pathological features and the treatment effect of bicalutamide on TTF. Pathological subgroups in which SRT failed to improve TTF over SHT alone were defined as having reduced benefit from SRT. Results: Adverse pathological features associated with shorter TTF with limited SRT included Gleason score (≥8), GP5, tertiary GP5, IDC-P, positive surgical margins, lymphovascular invasion, and advanced pathological T stage. Exploratory Interaction analyses suggested that IDC-P and tertiary GP5 may be associated with reduced relative benefit from SRT. Among patients without IDC-P, SRT significantly improved TTF (HR 0.330, 95%CI 0.161–0.673), whereas no significant benefit was observed in those with IDC-P (HR: 0.771, 95% CI: 0.446–1.332). Similarly, the absence of tertiary GP5 was associated with a marked benefit from SRT (HR: 0.099, 95% CI: 0.021–0.466), whereas this effect was not observed with tertiary GP5 (HR: 0.760, 95% CI: 0.400–1.443). Conclusions: IDC-P and tertiary GP5 may represent pathological features associated with reduced relative benefit from SRT after radical prostatectomy. These findings are exploratory and hypothesis-generating and require prospective validation in independent cohorts. Careful pathological evaluation may help identify patients who could benefit from treatment intensification or alternative postoperative strategies.
Open AccessPathological Predictors of Limited Salvage Radiotherapy Efficacy After Radical Prostatectomy: Central Review of JCOG0401
Background/Objectives: The multicenter randomized trial JCOG0401 showed that initial salvage radiotherapy (SRT) before salvage hormonal therapy (SHT) significantly prolonged time to treatment failure (TTF) compared with SHT alone. This central pathology analysis aimed to explore pathological features potentially associated with reduced relative benefit from SRT, while distinguishing prognostic from predictive effects. Methods: We re-analyzed 167 patients from JCOG0401 (SHT: 81, SRT ± SHT: 86). Prostatectomy specimens were re-evaluated, focusing on tertiary Gleason pattern (GP) 5 and intraductal carcinoma of the prostate (IDC-P). Cox proportional hazards models assessed exploratory interaction effects between pathological features and the treatment effect of bicalutamide on TTF. Pathological subgroups in which SRT failed to improve TTF over SHT alone were defined as having reduced benefit from SRT. Results: Adverse pathological features associated with shorter TTF with limited SRT included Gleason score (≥8), GP5, tertiary GP5, IDC-P, positive surgical margins, lymphovascular invasion, and advanced pathological T stage. Exploratory Interaction analyses suggested that IDC-P and tertiary GP5 may be associated with reduced relative benefit from SRT. Among patients without IDC-P, SRT significantly improved TTF (HR 0.330, 95%CI 0.161–0.673), whereas no significant benefit was observed in those with IDC-P (HR: 0.771, 95% CI: 0.446–1.332). Similarly, the absence of tertiary GP5 was associated with a marked benefit from SRT (HR: 0.099, 95% CI: 0.021–0.466), whereas this effect was not observed with tertiary GP5 (HR: 0.760, 95% CI: 0.400–1.443). Conclusions: IDC-P and tertiary GP5 may represent pathological features associated with reduced relative benefit from SRT after radical prostatectomy. These findings are exploratory and hypothesis-generating and require prospective validation in independent cohorts. Careful pathological evaluation may help identify patients who could benefit from treatment intensification or alternative postoperative strategies.
- Open Access
- 24 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70583
Adrenocortical Carcinoma in Peutz–Jeghers Syndrome With a Rare STK11 Pathogenic Germline Variant: A Case Report
Background: Peutz–Jeghers syndrome (PJS) is an inherited, autosomal‐dominant condition, featuring STK11 germline mutations, characterized by hamartomatous gastrointestinal polyps and increased cancer risk. The most commonly associated malignancies are gastrointestinal, pancreatic, and breast cancers. Herein, we report an extremely rare case of PJS with adrenocortical carcinoma (ACC). Case: A 40‐year‐old woman was referred to University of Tsukuba Hospital with uncontrolled diabetes mellitus (DM) and hypokalemia in July 2021. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a 12 cm mass in the right adrenal gland and aortocaval lymph node swelling. Mucocutaneous hyperpigmentation in her lips and fingertips was observed, and multiple stomach and small intestine polyps were visible on CT. We performed open right adrenalectomy with right nephrectomy, partial hepatectomy, and aortocaval lymph node dissection before diagnosing ACC with lymph node metastasis from the pathology. After surgery, multiple lung and liver metastases developed, and combination chemotherapy (etoposide, doxorubicin, and cisplatin, plus mitotane) was started, achieving stable disease for 2 years. We also performed an OncoGuide NCC Oncopanel on the adrenal tumor specimen and blood sample, revealing a rarely reported pathogenic germline variant (c.394T>C, p.C132R) in STK11 . This variant was registered as Likely Pathogenic in the NIH Clinvar public database, which led to a PJS diagnosis. Conclusion: This is the second report of ACC associated PJS in a rare germline variant of STK11 . Although rare, loss of STK11 function may lead to cancers outside expected sites in PJS cases.
- 24 May 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (5) , e70583
Open AccessAdrenocortical Carcinoma in Peutz–Jeghers Syndrome With a Rare STK11 Pathogenic Germline Variant: A Case Report
Background: Peutz–Jeghers syndrome (PJS) is an inherited, autosomal‐dominant condition, featuring STK11 germline mutations, characterized by hamartomatous gastrointestinal polyps and increased cancer risk. The most commonly associated malignancies are gastrointestinal, pancreatic, and breast cancers. Herein, we report an extremely rare case of PJS with adrenocortical carcinoma (ACC). Case: A 40‐year‐old woman was referred to University of Tsukuba Hospital with uncontrolled diabetes mellitus (DM) and hypokalemia in July 2021. Computed tomography (CT) and magnetic resonance imaging (MRI) revealed a 12 cm mass in the right adrenal gland and aortocaval lymph node swelling. Mucocutaneous hyperpigmentation in her lips and fingertips was observed, and multiple stomach and small intestine polyps were visible on CT. We performed open right adrenalectomy with right nephrectomy, partial hepatectomy, and aortocaval lymph node dissection before diagnosing ACC with lymph node metastasis from the pathology. After surgery, multiple lung and liver metastases developed, and combination chemotherapy (etoposide, doxorubicin, and cisplatin, plus mitotane) was started, achieving stable disease for 2 years. We also performed an OncoGuide NCC Oncopanel on the adrenal tumor specimen and blood sample, revealing a rarely reported pathogenic germline variant (c.394T>C, p.C132R) in STK11 . This variant was registered as Likely Pathogenic in the NIH Clinvar public database, which led to a PJS diagnosis. Conclusion: This is the second report of ACC associated PJS in a rare germline variant of STK11 . Although rare, loss of STK11 function may lead to cancers outside expected sites in PJS cases.
- Open Access
- 7 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (5) , e70403
Impact of European Association of Urology Combination and Platinum Eligibility on Real‐World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma
Objectives: To evaluate the prevalence of European Association of Urology‐defined combination and platinum eligibility at first‐line treatment initiation, and to assess their impact on conventional treatment sequence and overall survival in a real‐world Japanese cohort. Methods: We retrospectively analyzed 148 patients with metastatic urothelial carcinoma who initiated systemic chemotherapy between 2018 and 2024 at a single institution in Japan. Cisplatin eligibility was assessed according to the Galsky criteria. Combination therapy eligibility and platinum eligibility were defined according to the European Association of Urology guideline. Results: Among the 148 patients, 128 (86.5%) were combination‐eligible and 20 (13.5%) ineligible. Among combination‐eligible patients, 70 (54.7%) were cisplatin‐eligible, 47 (36.7%) cisplatin‐ineligible but platinum‐eligible, and 11 (8.6%) platinum‐ineligible. Median overall survival was significantly longer in combination‐eligible patients than in combination‐ineligible patients (25 vs. 16 months, p = 0.019, HR 2.46, 95% CI 1.16–5.23). Within the combination‐eligible group, cisplatin‐eligible patients tended to show superior median overall survival (not reached) compared with cisplatin‐ineligible/platinum‐eligible (25 months) and platinum‐ineligible (15 months, p = 0.11 and p = 0.082, respectively). Only 25.0% (32/128) of combination‐eligible patients received the chemotherapy–immune checkpoint inhibitor–enfortumab vedotin sequence, while 20.0% (4/20) of combination‐ineligible patients also completed this sequence. Conclusions: European Association of Urology‐defined combination and platinum eligibility were associated with survival outcomes and treatment sequence capability in a real‐world setting. These findings highlight the prognostic value but practical limitations of eligibility criteria, emphasizing the need to develop more practical classification frameworks that ensure broader access to effective therapy.
- 7 May 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (5) , e70403
Open AccessImpact of European Association of Urology Combination and Platinum Eligibility on Real‐World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma
Objectives: To evaluate the prevalence of European Association of Urology‐defined combination and platinum eligibility at first‐line treatment initiation, and to assess their impact on conventional treatment sequence and overall survival in a real‐world Japanese cohort. Methods: We retrospectively analyzed 148 patients with metastatic urothelial carcinoma who initiated systemic chemotherapy between 2018 and 2024 at a single institution in Japan. Cisplatin eligibility was assessed according to the Galsky criteria. Combination therapy eligibility and platinum eligibility were defined according to the European Association of Urology guideline. Results: Among the 148 patients, 128 (86.5%) were combination‐eligible and 20 (13.5%) ineligible. Among combination‐eligible patients, 70 (54.7%) were cisplatin‐eligible, 47 (36.7%) cisplatin‐ineligible but platinum‐eligible, and 11 (8.6%) platinum‐ineligible. Median overall survival was significantly longer in combination‐eligible patients than in combination‐ineligible patients (25 vs. 16 months, p = 0.019, HR 2.46, 95% CI 1.16–5.23). Within the combination‐eligible group, cisplatin‐eligible patients tended to show superior median overall survival (not reached) compared with cisplatin‐ineligible/platinum‐eligible (25 months) and platinum‐ineligible (15 months, p = 0.11 and p = 0.082, respectively). Only 25.0% (32/128) of combination‐eligible patients received the chemotherapy–immune checkpoint inhibitor–enfortumab vedotin sequence, while 20.0% (4/20) of combination‐ineligible patients also completed this sequence. Conclusions: European Association of Urology‐defined combination and platinum eligibility were associated with survival outcomes and treatment sequence capability in a real‐world setting. These findings highlight the prognostic value but practical limitations of eligibility criteria, emphasizing the need to develop more practical classification frameworks that ensure broader access to effective therapy.
- Open Access
- 10 March 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (3) , e70399
Current Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan
Objectives: Sex cord‐stromal tumors (SCSTs) constitute approximately 5% of testicular malignancies. This investigation aimed to elucidate contemporary therapeutic approaches and clinical outcomes for patients with testicular SCSTs in Japan. Methods: Participating institutions included Japan Clinical Oncology Group facilities, affiliated centers, and institutions with published cases. Clinical data and histopathological findings were compiled. Central pathological review involved representative tissue sections when available. Kaplan–Meier methodology assessed recurrence‐free survival (RFS) and overall survival (OS). Stage I patients were stratified by cumulative pathological risk factors (tumor diameter ≥ 5 cm, necrosis, moderate to severe nuclear atypia, lymphovascular invasion, infiltrative growth, and ≥ 3 mitoses per 10 high‐power fields). Results: Among 116 patients from 66 institutions, 112 met inclusion criteria. Histological distribution included Leydig cell ( n = 54), Sertoli cell ( n = 36), and other variants ( n = 22). Twelve patients presented with metastatic disease; ten received systemic chemotherapy, with 20.8% five‐year OS. Among 91 stage I patients with follow‐up data, eleven developed recurrence. Patients with > 2 risk factors demonstrated significantly inferior RFS compared with those showing ≤ 1 factor (26.4 versus 98.6% at 5 years, p < 0.0001). Surgical intervention predominated in the recurrent cases (81.8%, 9/11), while chemotherapy was administered to 45.5% (5/11), and selected patients achieved prolonged disease control through repeated surgical resection without systemic therapy. OS rates were 90.9% and 50.5% at 5 and 10 years. Conclusions: Patients with synchronous metastatic presentation demonstrated poor survival. Stage I patients with > 2 pathological risk factors showed reduced RFS, with surgical management potentially efficacious for recurrent disease.
- 10 March 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (3) , e70399
Open AccessCurrent Treatment Patterns and Outcomes of Sex Cord Stromal Tumor Patients in Japan
Objectives: Sex cord‐stromal tumors (SCSTs) constitute approximately 5% of testicular malignancies. This investigation aimed to elucidate contemporary therapeutic approaches and clinical outcomes for patients with testicular SCSTs in Japan. Methods: Participating institutions included Japan Clinical Oncology Group facilities, affiliated centers, and institutions with published cases. Clinical data and histopathological findings were compiled. Central pathological review involved representative tissue sections when available. Kaplan–Meier methodology assessed recurrence‐free survival (RFS) and overall survival (OS). Stage I patients were stratified by cumulative pathological risk factors (tumor diameter ≥ 5 cm, necrosis, moderate to severe nuclear atypia, lymphovascular invasion, infiltrative growth, and ≥ 3 mitoses per 10 high‐power fields). Results: Among 116 patients from 66 institutions, 112 met inclusion criteria. Histological distribution included Leydig cell ( n = 54), Sertoli cell ( n = 36), and other variants ( n = 22). Twelve patients presented with metastatic disease; ten received systemic chemotherapy, with 20.8% five‐year OS. Among 91 stage I patients with follow‐up data, eleven developed recurrence. Patients with > 2 risk factors demonstrated significantly inferior RFS compared with those showing ≤ 1 factor (26.4 versus 98.6% at 5 years, p < 0.0001). Surgical intervention predominated in the recurrent cases (81.8%, 9/11), while chemotherapy was administered to 45.5% (5/11), and selected patients achieved prolonged disease control through repeated surgical resection without systemic therapy. OS rates were 90.9% and 50.5% at 5 and 10 years. Conclusions: Patients with synchronous metastatic presentation demonstrated poor survival. Stage I patients with > 2 pathological risk factors showed reduced RFS, with surgical management potentially efficacious for recurrent disease.
- Open Access
- 23 January 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70466
Outcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single‐Center Study
Background: Enfortumab vedotin (EV) has demonstrated clinical benefits as a third‐line monotherapy after chemotherapy and immune checkpoint inhibitors and is currently established, in combination with pembrolizumab, as a first‐line standard therapy for metastatic urothelial carcinoma (mUC). However, dermatologic adverse events (DAEs) are common and may necessitate treatment interruption. While EV rechallenge is often considered, evidence regarding the recurrence and management of DAEs after rechallenge is limited. Aims: To analyze the incidence, timing, and severity of DAEs following EV rechallenge and assess the impact of dose modifications and initial inpatient versus outpatient management on clinical outcomes. Methods and Results: This retrospective observational study included patients with mUC who received EV at a single institution between January 2022 and December 2024. Of the 48 patients treated with EV, 36 (75.0%) developed DAEs, with a median onset of 11 days. Twenty patients resumed EV after interruption due to DAEs; 13 (65%) experienced recurrence. Recurrent DAEs tended to be of lower grade than the initial events and to be similar to the initial episode in terms of the type of DAEs. Early‐onset (≤ 7 days) DAEs were more likely to progress to grade ≥ 3. Although inpatient management enabled earlier detection and intervention, it did not reduce the incidence of severe toxicity compared to outpatient care. Conclusion: DAEs frequently recur after EV rechallenge but are typically less severe than the initial episode. Early‐onset DAEs may predict severe toxicity, underscoring the need for close monitoring and proactive management. Prospective studies are warranted to optimize rechallenge strategies and improve the safety of EV therapy.
- 23 January 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (1) , e70466
Open AccessOutcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single‐Center Study
Background: Enfortumab vedotin (EV) has demonstrated clinical benefits as a third‐line monotherapy after chemotherapy and immune checkpoint inhibitors and is currently established, in combination with pembrolizumab, as a first‐line standard therapy for metastatic urothelial carcinoma (mUC). However, dermatologic adverse events (DAEs) are common and may necessitate treatment interruption. While EV rechallenge is often considered, evidence regarding the recurrence and management of DAEs after rechallenge is limited. Aims: To analyze the incidence, timing, and severity of DAEs following EV rechallenge and assess the impact of dose modifications and initial inpatient versus outpatient management on clinical outcomes. Methods and Results: This retrospective observational study included patients with mUC who received EV at a single institution between January 2022 and December 2024. Of the 48 patients treated with EV, 36 (75.0%) developed DAEs, with a median onset of 11 days. Twenty patients resumed EV after interruption due to DAEs; 13 (65%) experienced recurrence. Recurrent DAEs tended to be of lower grade than the initial events and to be similar to the initial episode in terms of the type of DAEs. Early‐onset (≤ 7 days) DAEs were more likely to progress to grade ≥ 3. Although inpatient management enabled earlier detection and intervention, it did not reduce the incidence of severe toxicity compared to outpatient care. Conclusion: DAEs frequently recur after EV rechallenge but are typically less severe than the initial episode. Early‐onset DAEs may predict severe toxicity, underscoring the need for close monitoring and proactive management. Prospective studies are warranted to optimize rechallenge strategies and improve the safety of EV therapy.